Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT327 in Combination With Chemotherapy in First-line Non-small Cell Lung Cancer
NCT06712316Phase 3Recruiting
- Sponsor
- BioNTech SE
- Start
- Jan 2025
- Primary completion
- Jan 2029
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 22
01
Overview
Phase 3, randomised, open-label trial of pumitamig in non-small cell lung cancer (NSCLC) (10 arms), sponsored by BioNTech SE. Primary endpoints: Treatment-Emergent Adverse Events, Dose Interruption, Reduction, and Discontinuation and 3 more. Started Jan 2025; status: recruiting.
02
Drugs
pumitamig
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06712316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06712316.